# ProKidney Appoints Kenneth Locke as Chief Technical Officer
Canonical URL: https://biopharmsignal.com/news/PROK/prokidney-appoints-kenneth-locke-as-chief-technical-officer
Ticker: PROK
Company: ProKidney
Source: ProKidney
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.prokidney.com
## Summary

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) --

## Article Body
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) --
## Recent Company News
- 2026-06-25 13:46 EST — [ProKidney Appoints Kenneth Locke as Chief Technical Officer](https://biopharmsignal.com/news/PROK/prokidney-appoints-kenneth-locke-as-chief-technical-officer) — Source: ProKidney
- 2026-06-25 13:46 EST — [ProKidney Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/PROK/prokidney-reports-first-quarter-2026-financial-results-and-business-highlights) — Source: ProKidney
- 2026-06-25 13:46 EST — [ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel](https://biopharmsignal.com/news/PROK/prokidney-announces-alignment-with-the-fda-on-the-accelerated-approval-pathway-for-rilparencel) — Source: ProKidney
- 2026-06-25 13:46 EST — [ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates](https://biopharmsignal.com/news/PROK/prokidney-reports-second-quarter-2025-financial-results-and-provides-regulatory-and-clinical-updates) — Source: ProKidney
- 2026-06-25 13:46 EST — [ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference](https://biopharmsignal.com/news/PROK/prokidney-to-participate-in-two-upcoming-conferences-the-citi-biopharma-back-to-school-conference-and-the-morgan-stanley-global-healthcare-conference) — Source: ProKidney
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)